Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

ts are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. These and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACTS:

Investors: Media

John Quirk Cory Tromblee, both of

Porter Novelli Life Sciences Porter Novelli Life Sciences

(212) 601-8296
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  iMD Companies, Inc. (ICBU) ... to increase market share and grab a foothold in the ... influence, production capabilities and a presence in the sector, and ... facilitate the growth of hemp and medical marijuana, iMD is ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... reimbursement rates for home medical equipment and services (HME) ... as a result of Medicare,s bidding program going into ... largest metropolitan areas in the U.S. ... City, Miami, Orlando, Pittsburgh, and Riverside, California. The bidding ...
... Pa., Dec. 16, 2010 West Pharmaceutical Services, Inc. (NYSE: ... approved payment of the first-quarter 2011 cash dividend of $0.17 per ... shareholders of record on January 19, 2011. ... components and systems for injectable drug delivery, including stoppers and seals ...
Cached Medicine Technology:Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 2Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 3
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... the first to use a new tool to identify the ... of what these microscopic signatures or biomarkers should look like. ... Journal of Proteome Research, the advance could one day lead ... cancer as well as other diseases. , With many diseases, ...
... Provides Interventional Cardiologists with Enhanced ... Faster, More Precise Procedures, CHICAGO, March 31 According ... 1 killer,with an average of one death every 37 seconds. ... contributed to the surge of,Americans with cardiac issues. To address ...
... on Blue Cross ... EAGAN, Minn., March 31 In a peer-reviewed ... Cross and Blue,Shield of Minnesota (Blue Cross) reports that ... visits to the emergency room and,had an 11 percent ...
... medication, study finds , , MONDAY, March 31 (HealthDay News) ... diabetes drug, Amaryl, at slowing clogging of the arteries ... disease. , The Cleveland Clinic researchers behind the new ... diabetes medication has been shown to slow atherosclerosis, giving ...
... 2008 New data from a clinical trial ... patients living with type 2 diabetes, ACTOS® (pioglitazone ... arteries compared to glimepiride, and prevented progression compared ... PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic ...
... Considered by many in medical,marketing to be ... Ferdinand has joined,prominent Houston healthcare and sports marketing ... and Business Development., In her new role ... counsel for existing clients, and develop relationships,with potential ...
Cached Medicine News:Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 4Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 3Health News:Diabetes Drug Slows Clogging of Arteries 2Health News:Diabetes Drug Slows Clogging of Arteries 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination 2
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
MVR Blades for water tight self sealing incision....
... Edgeahead Stiletto / MVR knife. 1.1 mm (19G) ... 1.1 mm (19G) Cannula (5/bx, 1 bx/ca). State-of-the-art ... consistently sharp and precise. Sure grip handles have ... tip creates a fluid tight incision for self-sealing ...
Lens Plus Daily Cleaner is the preservative-free daily cleaner for soft contact lenses....
Medicine Products: